About

Exterior, Garside Building

About

Working across boundaries – pluralistic, integrative and non-exclusive

The Manchester Interdisciplinary Biocentre was completed in 2006 and represented the first university-based, purpose-built interdisciplinary research institute of its kind in the UK.

Focusing on advanced quantitative approaches to specific biotechnology challenges at the interface between medicine and biology and the physical sciences, engineering, mathematics and computation the MIB enjoys a unique pluralistic and open research culture that is supported by world-class infrastructure. The establishment of multi-skilled interdisciplinary teams with critical mass generates unique capabilities that cannot be realised through virtual associations between PIs or research units to develop regional, national and international partnerships in biotechnology research.

Manchester Institute of Biotechnology

Our areas of research both inform and are informed by our Research Grand Challenges which centre on emerging areas of excellence in the wider biotechnology field. Driving consortium grants and excellent team based research in this and related areas the MIB was renamed the Manchester Institute of Biotechnology in Autumn 2012, capturing in the institute name our leading research activity and focus in the many areas of biotechnology, including medical biotechnology and therapeutics, biofuels and energy and industrial biotechnology.

Advancing the University agenda

The University of Manchester is a world-renowned centre for scholarship and research and one of the world’s leading centres for biomedical and biotechnology research that sits at the forefront of new discoveries in science and engineering. The University exhibits a higher education brand synonymous with the finest international standards of academic excellence matching the world’s leading universities in attracting the highest calibre of researchers, innovators and scholars.

Research is at the heart of The University of Manchester and the scale, diversity and quality of its research activity is unrivalled in the UK. The outstanding results of the 2008 Research Assessment Exercise confirmed The University of Manchester as a genuine research powerhouse and one of the UK’s premier research institutions.

A distinctive feature of the University is its commitment to a social responsibility agenda aimed at enhancing the lives of all people, from local communities to international populations, through knowledge transfer and education. This commitment is embedded in global challenges that constitute the unique research vision of the MIB whose role is central to advancing the research mission of the University.


About – recent grant successes

Recent Grant Successes

BBSRC sLola: Nicholas Turner (PI), Eyers, Flitsch, Goodacre, Leys, Micklefield, Scrutton

Rapid Evolution of Enzymes and Synthetic Micro-organisms for the Development of Industrial Biocatalysts

03-Sep-12 to 02-Sep-17 Value: £4.5M plus £0.5M from GSK (All MIB).

EU: Nicholas Turner (PI) and Sabine Flitsch

Chemical Manufacturing Methods for the 21st Century Pharmaceutical Industries.

01-Oct-12 to 30-Sep-16 Value; £25M (£1.2M to MIB).

EPSRC Fellowship: Paul Popelier (PI)

Reliable Computational Prediction of Molecular Assembly
01-Apr-13 to 31-Mar-18 Value: £1.25M.

EPSRC Fellowship: Nigel Scrutton (PI)

Catalysis in motion: accessing how fast motions facilitate catalysis through pump-probe and fast time resolved spectroscopies.

01-Jul-12 to 30-Jun-17 Value: £1.06M.

BBSRC sLola: Jason Micklefield (PI)

Exploiting Natural Product Assembly Line Genomics and Synthetic Biology for Discovery and Optimisation of Novel Agrochemicals

Value: £0.87M to MIB (£5M grant with Warwick and Syngenta).

BBSRC sLola: Claire Eyers (CoI)

Systems Biology analysis of biological timers and inflammation.

03-Sep-12 to 02-Sep-17 Value: £4.4M to UoM (£290K to MIB) Jackson, Loudon, Muldoon, Paszek, Ray, Spiller, White (PI).

BBSRC IPA with GSK: Nigel Scrutton (PI), Pedro Mendes, John Gardiner and David Leys

Industrial chemicals of the monoterpenoid class realised through synthetic biology and pathway engineering

01-Aug-12 to 31-Jul-16 Value: £0.9M.

Industry (Siemens plc): Nenadic Goran (CoI) and Bijan Parsia.

Integration of dynamic documentation knowledge services into siemen’s framework

01-Jan-12 to 31-Dec-13 Value: £1.02M (£0.5M to MIB).